medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (4)

Differential diagnosis of hemolytic anemias

Soler NG, González GM, Forrellat BM

Language: Spanish
References: 35
Page: 1-19
PDF size: 381.26 Kb.


ABSTRACT

Introduction: The term hemolysis refers to the destruction of erythrocytes, a process occurring in a wide range of physiological and pathological clinical conditions. The term is used to define situations in which mean erythrocyte lifespan is reduced due to mechanical, toxic, autoimmune or infectious causes.
Objective: Describe the main markers of hemolysis found to be variably altered in the different forms of hemolytic anemias.
Methods: A review was conducted of the literature about the topic published in English and Spanish in the website PubMed and the search engine Google Scholar in the last 10 years. Data were analyzed and summarized.
Data analysis and synthesis: Hemoglobin is the most direct marker of clinical severity in hemolytic diseases. Its values may be very close to reference levels in mild disease (Hb > 100 g/l), whereas they will be significantly reduced in moderate (Hb 80-100 g/l), severe (Hb 60-80 g/l) and very severe disease (Hb < 60 g/l). However, other markers are also essential to distinguish acute from chronic presentation, extravascular from intravascular hemolysis, and the presence of extrahematological signs such as reticulocytes and schistocytes, lactate dehydrogenase, haptoglobin, bilirubin, ferritin and hemosiderinuria.
Conclusions: Differentially altered hemolytic parameters may be found in several conditions, which makes them useful for the differential diagnosis of hemolytic anemias.


REFERENCES

  1. Russo R, Gambale A, Langella C, Andolfo I, Unal S, Iolascon A. Retrospective cohort study of 205 cases with congenital dyserythropoietic anemia type II: definition of clinical and molecular spectrum and identification of new diagnostic scores. Am J Hematol. 2014; 89(10):E169-75. DOI: http://10.1002/ajh.23800

  2. Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014; 124(19):2930-6. DOI: http://10.1182/blood-2014-06-583021

  3. Arndt PA, Leger RM, Garratty G. Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. Transfusion. 2009; 49:235-42. DOI: http://10.1111/j.1537-2995.2008.01957.x

  4. Barcellini W, Fattizzo B. Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia. Dis Markers. 2015; 2015:635670. DOI: http://10.1155/2015/635670

  5. Garrett F, Bassa ET, Tuscano JM. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmunity Rev. 2014; 13:560-4. DOI: http://10.1016/j.autrev.2013.11.010

  6. Petz LD, Garratty G. Immune Hemolytic Anemias. 2nd ed. Philadelphia: Churchill Livingstone; 2004.

  7. Bope ET, Kellerman RD. Hematology. In: Bope ET, Kellerman RD, eds. Conn's Current Therapy 2016. Philadelphia: Elsevier; 2016.

  8. Aladjidi N, Leverger G, Leblanc T, Picat MQ, Michel G, Bertrand Y, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011; 96(5):655-63. DOI: http://10.3324/haematol.2010.036053

  9. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014; 124(18): 2804-11. DOI: http://10.1182/blood-2014-02-522128

  10. Fadeyi EA, Simmons JH, Jones MR, Palavecino EL, Pomper GJ. Fatal Autoimmune Hemolytic Anemia Due to Immunoglobulin G Autoantibody Exacerbated by Epstein-Barr Virus. Lab Med. 2015; 46(1):55-9. DOI: http://org/10.1309/LM9OWRF64OGQODEA

  11. Christoforidou A, Fasoulakis Z, Kontomanolis EN. Diagnosis and Management of Congenital Dyserythropoietic Anaemia Type II in a Secundigravida. Cureus. 2017; 9(10):e1811. DOI: http://10.7759/cureus.1811

  12. Salama A, Hartnack D, Lindemann HW, Lange HJ, Rummel M, Loew A. The effect of erythropoiesis-stimulating agents in patients with therapy-refractory autoimmune hemolytic anemia. Transfus Med Hemother. 2014; 41(6):462-8. DOI: http://10.1159/000366244

  13. Huisjes R, van Solinge WW, Levin MD, van Wijk R, Riedl JA. Digital microscopy as a screening tool for the diagnosis of hereditary hemolytic anemia. Int J Lab Hematol. 2018; 40(2):159-68. DOI: http://10.1111/ijlh.127588

  14. van Straaten S, Bierings M, Bianchi P, Akiyoshi K, Kanno H, Serra IB, et al. Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency. Haematologica. 2018; 103(2):e82-6. DOI: http://10.3324/haematol.2017.177857

  15. Mancuso S, Sucato G, Carlisi M, Santoro M, Tarantino G, Iannitto E, et al. Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs. Hematol Rep. 2018; 10(1):7523. DOI: http://10.4081/hr.2018.7523

  16. Suh YJ, Kim YJ, Kim JY, Chang S, Im DJ, Hong YJ, et al. A whole-heart motion-correction algorithm: Effects on CT image quality and diagnostic accuracy of mechanical valve prosthesis abnormalities. J Cardiovasc Comput Tomogr. 2017; 11(6):474-81. DOI: http://10.1016/j.jcct.2017.09.011

  17. Hrdinová J, D & apos;Angelo S, Graça NAG, Ercig B, Vanhoorelbeke K, Veyradier A, et al. Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. Haematologica. 2018 Jul;103(7):1099-1109. DOI: http://10.3324/haematol.2016.151407

  18. Schuppner R, Dirks M, Grosse GM, Böckmann M, Goetz F, Pasedag T, et al. ADAMTS-13 Activity Predicts Outcome in Acute Ischaemic Stroke Patients Undergoing Endovascular Treatment. Thromb Haemost. 2018; 118(4):758-67. DOI: http://10.1055/s-0038-1637732

  19. Gupta M, Feinberg BB, Burwick RM. Thrombotic microangiopathies of pregnancy: Differential diagnosis. Pregnancy Hypertens. 2018; 12:29-34. DOI: http://10.1016/j.preghy.2018.02.007

  20. Yildiz S, Demirkan F. What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies? Transfus Apher Sci. 2018; 57(1):31-4. DOI: http://10.1016/j.transci.2018.02.013

  21. Quinn CT, Smith EP, Arbabi S, Khera PK, Lindsell CJ, Niss O, et al. Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia. Am J Hematol. 2016;1(12):1195-1201. DOI: http://10.1002/ajh.24562

  22. Pourrat O, Coudroy R, Pierre F. Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators. Eur J Obstet Gynecol Reprod Biol. 2015;189:68-72. DOI: http://10.1016/j.ejogrb.2015.03.017

  23. Walter K, Vaughn J, Martin D. Therapeutic dilemma in the management of a patient with the clinical picture of TTP and severe B12 deficiency. BMC Hematol. 2015;15:16. DOI: http://10.1186/s12878-015-0036-2

  24. Garton T, Keep RF, Hua Y, Xi G. CD163, a Hemoglobin/Haptoglobin Scavenger Receptor, After Intracerebral Hemorrhage: Functions in Microglia/Macrophages Versus Neurons. Transl Stroke Res. 2017; 8(6):612-6. DOI: http://10.1007/s12975-017-0535-5

  25. Cholette JM, Pietropaoli AP, Henrichs KF, Alfieris GM, Powers KS, Gensini F, et al. Elevated free hemoglobin and decreased haptoglobin levels are associated with adverse clinical outcomes, unfavorable physiologic measures, and altered inflammatory markers in pediatric cardiac surgery patients. Transfusion. 2018 Jul;58(7):1631-9. DOI: http://10.1111/trf.14601

  26. Peta V, Tse C, Perazzo H, Munteanu M, Ngo Y, Ngo A, et al. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. PLoS One. 2017;12(12):e0189436. DOI: http://10.1371/journal.pone.0189436

  27. Wurster WL, Pyne-Geithman GJ, Peat IR, Clark JF. Bilirubin oxidation products (BOXes): synthesis, stability and chemical characteristics. Acta Neurochir Suppl. 2008;104:43-50.

  28. Kumar A, Aggarwal V. Celiac Disease in Association with Gilbert's Syndrome. Indian J Pediatr . 2018 Sep;85(9):814-815. DOI: http://10.1007/s12098-018-2674-4

  29. Berlin NI Berk PD. Quantitative aspects of bilirubin metabolism for hematologists. Blood 1981; 57(6):983-99.

  30. Emilse LAM, Cecilia H, María TM, Eugenia MM, Alicia IB, Lazarte SS. Cryohemolysis, erythrocyte osmotic fragility, and supplementary hematimetric indices in the diagnosis of hereditary spherocytosis. Blood Res. 2018; 53(1):10-7. DOI: http://10.5045/br.2018.53.1.10

  31. Griffin M, Kulasekararaj A, Gandhi S, Munir T, Richards S, Arnold L, et al. Concurrent treatment of aplastic anemia/Paroxysmal Nocturnal Hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience. Haematologica. 2018 Aug;103(8):e345-e347. DOI: http://10.3324/haematol.2017.183046

  32. Garcia-Casal MN, Peña-Rosas JP, Urrechaga E, Escanero JF, Huo J, Martinez RX, et al. Performance and comparability of laboratory methods for measuring ferritin concentrations in human serum or plasma: A systematic review and meta-analysis. PLoS One. 2018; 13(5):e0196576. DOI: http://10.1371/journal.pone.0196576

  33. Röth A, Maciejewski J, Nishimura JI, Jain D, Weitz JI. Screening and Diagnostic Clinical Algorithm for Paroxysmal Nocturnal Hemoglobinuria: Expert Consensus. Eur J Haematol. 2018 Jul;101(1):3-11. DOI: http://10.1111/ejh.13059

  34. Martínez-Valdez L, Deyà-Martínez A, Giner MT, Berrueco R, Esteve-Solé A, Juan M, et al. Evans Syndrome as First Manifestation of Primary Immunodeficiency in Clinical Practice. J Pediatr Hematol Oncol. 2017; 39(7):490-4. DOI: http://10.1097/MPH.0000000000000880

  35. Dezern AE, Borowitz MJ. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 - clinical utility. Cytometry B Clin Cytom. 2018; 94(1):16-22. DOI: http://10.1002/cyto.b.21608




2020     |     www.medigraphic.com